Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Profund Advisors LLC

Profund Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 16,919 shares of the biopharmaceutical company’s stock after acquiring an additional 3,105 shares during the period. Profund Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $4,175,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Toth Financial Advisory Corp purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Keating Financial Advisory Services Inc. purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $42,000. Burkett Financial Services LLC purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $37,000. CoreCap Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 134 shares during the last quarter. Finally, Ascentis Independent Advisors bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $64,000. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $165.00 on Friday. The company has a market cap of $22.08 billion, a price-to-earnings ratio of 8.57 and a beta of 0.28. The firm’s fifty day moving average is $236.49 and its 200 day moving average is $286.19. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 52-week low of $163.30 and a 52-week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same period last year, the company posted $2.90 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current fiscal year.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. Sanford C. Bernstein downgraded shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $376.00 to $199.00 in a report on Friday. UBS Group reiterated a “buy” rating and issued a $329.00 price target (down from $550.00) on shares of Alnylam Pharmaceuticals in a report on Friday. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Friday. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Finally, HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $317.95.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.